PMID- 23362308
OWN - NLM
STAT- MEDLINE
DCOM- 20130812
LR  - 20130220
IS  - 1941-7632 (Electronic)
IS  - 1941-7640 (Linking)
VI  - 6
IP  - 1
DP  - 2013 Feb
TI  - Procedural safety and predictors of acute outcome of intracoronary administration 
      of progenitor cells in 775 consecutive procedures performed for acute myocardial 
      infarction or chronic heart failure.
PG  - 44-51
LID - 10.1161/CIRCINTERVENTIONS.112.971705 [doi]
AB  - BACKGROUND: Cell-based therapies are a promising option in patients with acute 
      myocardial infarction or chronic heart failure (CHF). However, administration of 
      cells requires intracoronary or intracardiac instrumentation, which is 
      potentially associated with periprocedural risks. Therefore, we analyzed 
      periprocedural complications and 30-day outcome in 775 consecutive procedures of 
      intracoronary administration of progenitor cells using the stop-flow technique. 
      METHODS AND RESULTS: Indications for cell administration were acute myocardial 
      infarction (n=126) and CHF of ischemic (n=562) or nonischemic (n=87) etiology. 
      Vessel injury was observed in a total of 9 procedures (1.2%) and could be 
      promptly managed by additional progenitor cell injection (PCI) in all but 1 case. 
      No procedural deaths were observed. A periprocedural increase in troponin T was 
      observed in 3.2% of the CHF procedures, in which no concomitant PCI was performed 
      and troponin levels were not elevated before the procedure. Independent 
      significant predictors of troponin T increase were higher New York Heart 
      Association (NYHA) class (NYHA I versus NYHA IV; P=0.01; NYHA I versus III; 
      P=0.19; NYHA I versus II; P=0.55), concomitant revascularization (P<0.01), 
      presence of elevated troponin T before the procedure (P<0.01), and peripheral 
      occlusive disease (P=0.04). At 30 days, there were 4 deaths (0.5%), 1 stroke 
      (0.13%), 8 acute myocardial infarctions (1%), and 5 hospitalizations for 
      exacerbation of heart failure (0.64%). CONCLUSIONS: Intracoronary infusion of 
      progenitor cells can be performed with adequate safety in patients with acute 
      myocardial infarction or CHF, because the safety profile was similar to what is 
      usually expected from a coronary angiogram in the present cohort. CLINICAL TRIAL 
      REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00962364, 
      NCT00284713, and NCT00289822.
FAU - De Rosa, Salvatore
AU  - De Rosa S
AD  - Division of Cardiology, Department of Medicine III, Goethe University Frankfurt, 
      Germany.
FAU - Seeger, Florian H
AU  - Seeger FH
FAU - Honold, Jorg
AU  - Honold J
FAU - Fischer-Rasokat, Ulrich
AU  - Fischer-Rasokat U
FAU - Lehmann, Ralf
AU  - Lehmann R
FAU - Fichtlscherer, Stephan
AU  - Fichtlscherer S
FAU - Schachinger, Volker
AU  - Schachinger V
FAU - Dimmeler, Stefanie
AU  - Dimmeler S
FAU - Zeiher, Andreas M
AU  - Zeiher AM
FAU - Assmus, Birgit
AU  - Assmus B
LA  - eng
SI  - ClinicalTrials.gov/NCT00284713
SI  - ClinicalTrials.gov/NCT00289822
SI  - ClinicalTrials.gov/NCT00962364
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130129
PL  - United States
TA  - Circ Cardiovasc Interv
JT  - Circulation. Cardiovascular interventions
JID - 101499602
RN  - 0 (Troponin T)
SB  - IM
MH  - Adult
MH  - Aged
MH  - American Heart Association
MH  - Bone Marrow Cells/*cytology
MH  - Chronic Disease
MH  - Coronary Angiography
MH  - Female
MH  - Heart Failure/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*surgery
MH  - New York
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - *Stem Cell Transplantation
MH  - Troponin T/*metabolism
MH  - United States
EDAT- 2013/01/31 06:00
MHDA- 2013/08/13 06:00
CRDT- 2013/01/31 06:00
PHST- 2013/01/31 06:00 [entrez]
PHST- 2013/01/31 06:00 [pubmed]
PHST- 2013/08/13 06:00 [medline]
AID - CIRCINTERVENTIONS.112.971705 [pii]
AID - 10.1161/CIRCINTERVENTIONS.112.971705 [doi]
PST - ppublish
SO  - Circ Cardiovasc Interv. 2013 Feb;6(1):44-51. doi: 
      10.1161/CIRCINTERVENTIONS.112.971705. Epub 2013 Jan 29.